PHOENIX, AZ--(Marketwired - Nov 20, 2013) - Insys Therapeutics, Inc. (
- The 25th Annual Piper Jaffray Healthcare Conference taking place at The New York Palace on December 3-4, 2013 in New York City. Management is scheduled to present on Tuesday, December 3, 2013 at 2:30 p.m. EST.
- The 24th Annual Oppenheimer Healthcare Conference taking place at the Crowne Plaza Hotel on December 10-11, 2013 in New York City. Management is scheduled to present on Tuesday, December 10, 2013 at 3:55 p.m. EST.
During these presentations, material information concerning the Company, its operations, strategies and prospects may be discussed. To listen to the audio webcast of these presentations during the event, please visit: www.insysrx.com. A replay of each webcast will be available for 30 days after the initial presentation.
About Insys Therapeutics, Inc.
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products, with a focus on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products. The company has two marketed products including Subsys, a proprietary sublingual fentanyl spray for breakthrough pain in opioid-tolerant cancer patients. Insys markets Subsys through its incentive-based, cost-efficient commercial sales force. The company's lead product candidate is Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol, which would be its second branded supportive care product, if approved.
Contact Information:
Contacts:
Darryl S. Baker
Chief Financial Officer
Insys Therapeutics, Inc.
602-910-2617
Lisa M. Wilson
President
In-Site Communications, Inc.
212-452-2793